Novo Nordisk Sues Lilly Over GLP-1 Ad Claims

What's Actually Happening Between Novo Nordisk and Eli Lilly

Novo Nordisk, the maker of Ozempic and Wegovy, has filed a lawsuit against Eli Lilly, the company behind Mounjaro and Zepbound. The core allegation: Lilly's advertising for its GLP-1 and GIP/GLP-1 medications contains claims that Novo Nordisk says are deceptive and misleading to patients and providers.

This kind of pharmaceutical litigation is more common than most people realize. When two of the world's largest drug companies are competing for a market that analysts estimate could exceed $100 billion globally within a decade, advertising language becomes high-stakes territory.

The lawsuit was filed in mid-2025 and centers on specific marketing claims Novo Nordisk believes misrepresent how Lilly's drugs compare to its own products. The full details of the specific claims at issue are being argued in court, but the broader message is clear: the GLP-1 space is intensely competitive, and both companies are watching each other closely.

Why This Lawsuit Matters If You're a Patient

If you're currently taking a GLP-1 medication or weighing your options, your first instinct might be to tune out corporate legal disputes. That's understandable. But this case has a few layers worth paying attention to.

Pharmaceutical advertising shapes what you hear in the doctor's office. Drug companies market directly to both consumers and physicians. If ads are making claims that exaggerate a drug's advantages or downplay a competitor's strengths, that information can filter into conversations with your prescriber, and eventually into your treatment decisions.

It signals how much the competitive pressure has escalated. Novo Nordisk held a dominant position in the GLP-1 market for years with semaglutide. When Eli Lilly launched tirzepatide (the active ingredient in Mounjaro and Zepbound), clinical trial data showed stronger average weight loss results. That disruption has clearly intensified the rivalry between the two companies.

It doesn't mean either drug is unsafe or ineffective. This is a dispute about advertising, not drug safety. The FDA approval status, clinical data, and prescribing guidelines for both medications remain unchanged. If you're already doing well on either drug, there's no reason to be alarmed.

Semaglutide vs. Tirzepatide: Cutting Through the Marketing Noise

One reason this lawsuit landed the way it did is because the comparison between these two drug classes is genuinely complex. Let's look at what peer-reviewed clinical trials actually show, separate from any company's marketing materials.

What the Clinical Data Says

Semaglutide (Ozempic, Wegovy) works by mimicking a hormone called GLP-1 (glucagon-like peptide-1), which regulates appetite and blood sugar. The STEP clinical trial program showed that semaglutide 2.4 mg led to an average body weight reduction of about 15% over 68 weeks in adults with obesity.

Tirzepatide (Mounjaro, Zepbound) targets two hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The SURMOUNT trial program showed average weight loss of up to 22.5% at the highest dose over 72 weeks.

These are averages from specific trial populations. Individual results vary based on starting weight, diet, activity, genetics, and other health factors.

Keep in mind: no head-to-head randomized clinical trial directly comparing semaglutide and tirzepatide at equivalent doses in equivalent populations has been published as of mid-2025. That gap in the data is exactly the kind of space where marketing claims can outrun the science.

How Drug Companies Advertise GLP-1 Medications

Pharmaceutical advertising in the United States operates under FDA oversight. Prescription drug ads must be truthful, balanced, and not misleading. But the rules around comparative advertising, which is when one brand directly or indirectly references a competitor, are nuanced and frequently litigated.

Common tactics that draw legal scrutiny include:

• Cherry-picking data points from studies conducted under different conditions to make one drug look superior
• Using surrogate endpoints such as lab values as proxies for outcomes that patients actually care about, like sustained weight loss or cardiovascular risk reduction
• Omitting key context such as the specific dose or patient population in a cited study
• Implying equivalence or superiority without a direct comparison trial to back it up

Novo Nordisk's lawsuit is essentially arguing that Lilly's ads crossed one or more of these lines. Lilly has not publicly conceded any wrongdoing, and the case will play out in court.

What This Means for Provider Marketing and Telehealth

The legal fight between Novo and Lilly isn't just happening on television. It's playing out in digital advertising, physician education materials, and in the growing world of telehealth prescribing platforms.

Many GLP-1 providers now market directly to patients online. Some are affiliated with or sponsored by specific manufacturers. Others prescribe compounded semaglutide or tirzepatide from third-party pharmacies, which operates in a completely different regulatory space than branded drugs.

When you're evaluating a telehealth platform or weight loss clinic, it's worth asking:

• Does this provider prescribe both semaglutide and tirzepatide options, or only one?
• Are their clinical recommendations driven by your specific health profile, or by a preferred formulary?
• Are they transparent about costs, including whether manufacturer coupons or savings cards apply?

A provider who can walk you through the actual published data, rather than repeating brand messaging, is the kind of prescriber worth finding. You can compare vetted options through our Best Providers guide.

How to Evaluate GLP-1 Claims on Your Own

With pharma companies suing each other over advertising, it's a reasonable moment to sharpen your own ability to evaluate health claims. Here's a practical framework.

Ask "Compared to what?"

Any claim about a drug's effectiveness needs a comparison point. Compared to placebo? Compared to a lower dose of the same drug? Compared to a competitor? The answer changes everything.

Check the dose and the population

A study showing 22% weight loss at the maximum tirzepatide dose in a highly adherent clinical trial population tells you something, but not necessarily how you'll respond at a starting dose in real-world conditions.

Look for independent sources

Organizations like the American Diabetes Association, the Obesity Society, and the New England Journal of Medicine publish independent clinical reviews that have no financial stake in which drug you choose.

Be skeptical of "superior" language without a source

If an ad, a provider, or even a well-meaning friend tells you one GLP-1 medication is definitively better than another, ask for the specific trial or study that supports that claim. Honest answers will come with caveats.

Cost, Access, and What the Lawsuit Doesn't Change

Legal disputes between manufacturers don't typically affect what you pay at the pharmacy counter. But pricing and access remain real concerns for anyone on these medications.

As of mid-2025, branded GLP-1 medications without insurance coverage can cost anywhere from $900 to $1,400 per month. Both Novo Nordisk and Eli Lilly offer savings programs, but eligibility requirements apply and they don't cover everyone.

For up-to-date savings options, check our GLP-1 Coupons page, which tracks current manufacturer and pharmacy discount programs.

The Bottom Line for GLP-1 Patients

The lawsuit between Novo Nordisk and Eli Lilly is a reminder that even the most scientifically grounded drug categories are not immune to aggressive marketing. Both companies have strong financial incentives to position their medications as the better choice, and that pressure can distort the way information reaches patients.

Here's what hasn't changed: both semaglutide and tirzepatide are FDA-approved, clinically studied medications that have helped millions of people manage obesity and type 2 diabetes. The differences between them are real, but nuanced. Neither is universally "best." The right choice depends on your individual health history, your prescriber's clinical judgment, your insurance coverage, and your ability to tolerate and adhere to the medication over the long term.

What this moment calls for is a higher standard of skepticism toward drug marketing, not toward the medications themselves. When a commercial, a sponsored article, or even a well-intentioned provider tells you one option is clearly superior, ask for the data. Ask what trial, what dose, what population, and what the comparison point was.

Questions to Bring to Your Next Appointment

• Based on my health history, which GLP-1 medication do you think is a better fit for me and why?
• Are there published studies comparing these two drugs directly?
• What are the main reasons patients switch from one GLP-1 to another?
• How do we measure whether my current medication is working well enough?
• Are there savings programs I should apply for given my insurance situation?

The legal system will sort out whether Lilly's advertising crossed a line. Your job, as a patient, is simply to make sure the information guiding your treatment comes from evidence, not from whoever has the bigger advertising budget.

If you're still in the process of comparing options, our Best Providers guide breaks down telehealth platforms by cost, drug availability, and patient experience. And if cost is your biggest barrier right now, the GLP-1 Coupons page tracks the latest savings programs from both Novo Nordisk and Eli Lilly, updated regularly.

As always, talk to your doctor or licensed prescriber before starting, stopping, or switching any GLP-1 medication.